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OBJECTIVES This study planned to establish whether sympathetic hyperactivity exists in white-coat
hypertension (WHT) in the clinical setting, relative to matched groups with normotension
(NT) and untreated essential hypertension (EHT).
BACKGROUND White-coat hypertension differs from EHT by the presence of normal ambulatory blood
pressure. Sympathetic hyperactivity exists in patients with EHT in the clinical setting and is
believed to contribute to the development of target organ damage. Similar organ damage has
been reported in WHT, yet little is known about sympathetic neural activity in this condition.
METHODS Using microneurography, we examined groups of 12 matched subjects with WHT, EHT and
NT during the same clinical setting to quantify muscle sympathetic nerve activity as multiunit
discharge (MSNA) and single units (s-MSNA).
RESULTS The s-MSNA in WHT (54  4.2 impulses/100 beats) was greater (p  0.05) than in NT
(37  5.4 impulses/100 beats) despite similar age and body mass index (BMI). The EHT
values of s-MSNA (73  5.2 impulses/100 beats) were significantly (p  0.05) greater than
in WHT despite similar age, BMI and blood pressure levels. The MSNA followed a similar
trend. White-coat hypertension had a similar cardiac baroreceptor reflex sensitivity to NT,
but this was impaired in EHT relative to both NT and WHT.
CONCLUSIONS It was shown, in the clinical setting, that central sympathetic hyperactivity exists in WHT,
albeit to a lesser degree than EHT. These findings suggest that WHT may not be entirely
benign and that the observed sympathetic hyperactivity may be responsible for development
of target organ damage in this group of patients. (J Am Coll Cardiol 2002;40:126–32)
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White-coat hypertension (WHT) is a condition that differs
from essential hypertension by the finding of a persistently
elevated clinic blood pressure in the presence of normal
ambulatory blood pressure values (1–4). Hyperactivity of
the sympathetic nervous system, assessed directly in the
clinical setting, has been implicated in the pathogenesis of
essential hypertension (EHT) (5–7) and in the development
of target organ damage (8,9). There has been a disagree-
ment as to whether (10–13), or not (14–17), a similar target
organ damage occurs in WHT, yet little is known about
sympathetic neural activity in this condition.
Using the technique of microneurography (18,19) to
quantify sympathetic discharge in the clinical setting, an
increase in the mean frequency of bursts (6,7,20), represent-
ing multiunit discharge of muscle sympathetic nerve activity
(MSNA) and activity from single unit (s-MSNA) discharge
(21), has been reported in patients with EHT, as compared
with matched normotensive subjects (NT). It has also been
shown that patients with mild hypertension combined with
“white-coat effect” have a reduction in MSNA during a
doctor’s visit to the clinic (22). However, while that report
involved patients with mild hypertension, there are no
reported data available regarding such an effect in patients
with WHT.
The vast majority of evidence regarding sympathetic
activity in WHT has been derived indirectly from indexes
such as the levels of circulating and urinary catecholamines,
renin activity, insulin and heart rate variability (1,23,24).
The results from these studies are variable, with daytime
sympathetic activity suggested as being either increased
(1,23) or normal (24).
This investigation was designed to examine whether
central sympathetic vasoconstrictor output to the peripheral
vascular bed is increased in the clinical setting in patients
with WHT, in the same way as it is in established EHT.
For this purpose, we studied matched groups of WHT and
EHT in terms of age, body mass index (BMI) and blood
pressure, and also a group with normal blood pressure
matched for age and BMI.
METHODS
Subjects. The study involved 36 Caucasian subjects who
were examined between 2000 and 2001 and in whom it was
possible to identify and record single-unit activity by the
technique of microneurography. They comprised 12 with
newly diagnosed and untreated EHT, 12 with WHT and
12 subjects with normal blood pressure (NT). Their age
ranges were 25 to 62 years, 23 to 64 years and 24 to 63 years,
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respectively. All had similar occupational status (sedentary
jobs) and dietary habits including a sodium intake of
approximately 400 mmol/day. All patients were screened by
history, physical and laboratory examination. Patients were
excluded if there was evidence of arrhythmia or chronic
disease that may influence the autonomic nervous system.
Similarly, patients with left ventricular hypertrophy, and
hypertension secondary to renal artery stenosis, phaeochro-
mocytoma and primary hyperaldosteronism were excluded
from the study.
The measured values of arterial pressure were based on
the average of at least three seated recordings taken on
separate occasions in the clinical setting. The groups were
classified using clinic blood pressure readings according to
Joint National Committee (JNC)-VI criteria (25). Normal
ambulatory blood pressure was strictly defined as a daytime
average of 130/80 mm Hg (11). Patients with WHT had
a sustained clinic blood pressure of 140/90 mm Hg with
a daytime ambulatory blood pressure of 130/80 mm Hg.
Patients with EHT had a similar level of clinic blood
pressure but ambulatory blood pressure of 130/80 mm
Hg. Subjects with normal blood pressure had an arterial
blood pressure of 130/85 mm Hg in the clinic and similar
ambulatory values to the WHT group. Patients with WHT
and EHT were matched for age, BMI and clinic blood
pressure level, and the NT group was matched for age and
BMI with the other two groups. The clinical details of the
three groups are given in Table 1, and their ambulatory
blood pressure data are shown in Table 2.
General protocol. Each subject provided informed written
consent to the investigation, which was performed under
the approval of the Leeds Health Authority Ethical Com-
mittee. The details of the protocol and data analysis have
been published previously (21). Briefly, all the studies were
performed under similar conditions between the hours of
09:00 AM and 12:00 PM, and subjects were asked to have a
light breakfast and to empty their bladder before commenc-
ing the study. They were also asked to avoid nicotine and
caffeine products for 12 h and alcohol and strenuous exercise
for 24 h before investigation. Arterial blood pressure was
measured from the arm using a standard mercury sphygmo-
manometer. Changes in heart rate and arterial blood pres-
sure were monitored and recorded using a standard electro-
cardiogram and a Finapres device, and blood flow to the
muscle of the left calf was obtained using standard venous
occlusion plethysmography. Peripheral sympathetic nerve
activity was recorded simultaneously by the technique of
microneurography.
Microneurography. Postganglionic muscle sympathetic
nerve activity was recorded from the right peroneal nerve as
previously described (18,19,21). Briefly, the neural signal
was amplified (50,000), and, for the purpose of generating
bursts representing multiunit discharge, the signal was
filtered (bandwidth of 700 Hz to 2,000 Hz) and integrated
(time constant 0.1 s). All data were digitized at 2,000
samples/s (8 bits) except for individual action potential
output, which was sampled at 12,000 samples/s.
Multiunit muscle sympathetic nerve activity was differ-
entiated from skin sympathetic activity and afferent activity
by previously accepted criteria (18,19,21). Single units
(s-MSNA) were obtained from the raw action potential
neurogram by adjusting the electrode position. An on-line
storage oscilloscope and fast monitor sweep was used to
confirm the presence of consistent action potential mor-
phology, as previously described (21,26). Only vasoconstric-
tor units were accepted and examined, the criteria of
acceptance being appropriate responses to spontaneous
changes in arterial blood pressure, the Valsalva maneuver
and isometric handgrip exercise. Measurement of calf vas-
cular resistance (CVR) confirmed the vasoconstrictor func-
tion of the observed neural activity.
The Valsalva maneuver was performed by asking the
subjects to exhale into a standard mercury manometer, at a
pressure of 40 mm Hg for 15 s, while a pneumograph was
observed to confirm correct performance of the test. The
sympathetic activity increased during the latter part of phase
II (blood pressure compensation) and/or phase III (release
of strain and fall in blood pressure) and decreased during
phase IV (increase and overshoot of blood pressure).
Spikes of s-MSNA were objectively counted in record-
ings taken over a period of at least 4 min using an electronic
discriminator and were quantified as mean frequency of
impulses per min and per 100 cardiac beats to avoid
interference by the length of the cardiac cycle (27). The
bursts of MSNA were identified by inspection when the
signal-to-noise ratio was greater than 3 and were quantified
in a similar manner. The variability of measuring both
s-MSNA and MSNA in this laboratory did not exceed 10%
(21). During the fourth phase of the Valsalva maneuver, the
slope of the best linear relation between the systolic blood
pressure and its pulse interval (phase 0) or the succeeding
one (phase 1) was used as an indicator for cardiac barore-
ceptor reflex sensitivity (BRS). This noninvasive technique
has been previously used to assess the gain of baroreceptor
reflex control of the vagal effect on the sinoatrial node
(28–31). Calf vascular resistance was obtained from the
Abbreviations and Acronyms
BMI  body mass index
BRS  cardiac baroreceptor reflex sensitivity
CVR  calf vascular resistance
EHT  essential hypertension
IVS  interventricular septal thickness
JNC  Joint National Committee
LVID  left ventricular internal diameter
LVM  left ventricular mass
LVMI  left ventricular mass index
MSNA  multiunit muscle sympathetic nerve activity
NT  normotension
PW  end-diastolic posterior wall thickness
s-MSNA  single-unit muscle sympathetic nerve activity
WHT  white-coat hypertension
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product of mean arterial blood pressure and the mean of at
least three measurements of calf blood flow during the
study.
Other procedures. Ambulatory blood pressure monitoring
was performed independently using an oscillometric device
(TRACKER NIBP2, Reynolds Medical Ltd., Hertford,
United Kingdom). This device has been shown (SunTech
Medical Instruments, Raleigh, North Carolina) to satisfy
the requirements of the Association for the Advancement of
Medical Instrumentations (AAMI, Arlington, Virginia),
with a difference from the reference auscultatory method of
5 8 mm Hg (mean SD). Throughout the monitoring
period, patients were asked to follow their ordinary daily
activities and to go to bed not later than midnight. Blood
pressure measurements were taken at half-hourly intervals
during the daytime and every hour at night, to avoid patient
discomfort. This frequency has been assessed in Leeds by
comparing it to measurements obtained every 15 min during
the day and every half-hour at night. The coefficient of
variation (proportion of one SD to the mean measurement)
for both systolic and diastolic pressure amounted to 6%.
Two-dimensional M-mode echocardiography (Philips
SONOS 5500, Philips Medical Systems) was used to
measure left ventricular dimensions in our subjects. Using
American Society of Echocardiography recommendations
(32), measurement of end-diastolic posterior wall thickness
(PW), left ventricular internal diameter (LVID) and inter-
ventricular septal thickness (IVS) were determined and
considered to represent left ventricular hypertrophy if mea-
sures of PW or IVS exceeded 11 mm. Left ventricular mass
(LVM) was calculated according to the Penn convention
(33) using the equation: LVM(g)  1.04 [(IVS  LVID 
PW)3  (LVID)3] 13.6 and, to account for body surface
area, left ventricular mass index (LVMI) was derived.
Statistics. One-way analysis of variance with Newman-
Keuls multiple post-test comparisons were used to compare
Table 1. Characteristics of the Three Subject Groups: NT, WHT and EHT in the Clinical
Setting
Variables NT WHT EHT
Comparisons
NT vs. WHT WHT vs. EHT
Number (women) 12 (6) 12 (8) 12 (6)
Age (yrs) 46  3.9 46  4.1 47  3.2 p  0.05 p  0.05
BMI (kg/m2) 28  0.8 28  0.9 27  0.9 p  0.05 p  0.05
Weight (kg) 81  3.4 81  3.5 78  4.0 p  0.05 p  0.05
Systolic BP (mm Hg) 129  1.7 157  4.3 155  3.4 p  0.001 p  0.05
Diastolic BP (mm Hg) 82  2.1 95  1.1 93  1.4 p  0.001 p  0.05
MAP (mm Hg) 98  2.2 116  1.9 114  1.3 p  0.001 p  0.05
Heart rate (beats/min) 64  2.7 75  2.4 66  1.7 p  0.01 p  0.05
PW thickness (mm) 8.3  0.7 8.7  0.5 9.6  0.2 p  0.05 p  0.05
IVS thickness (mm) 8.7  0.3 8.7  1.2 9.2  0.4 p  0.05 p  0.05
LVID (mm) 48.3  1.2 48.2  0.9 47.8  0.6 p  0.05 p  0.05
LVM (g) 159  9.5 164  15.5 180  3.4 p  0.05 p  0.05
LVMI (g/m2) 76  5.0 83  6.9 93  2.5 p  0.05 p  0.05
Data presented as mean  SEM. Numbers in parentheses refer to female gender. Statistical analyses between groups
(Newman-Keuls; one-way analysis of variance) are shown on the right.
BMI body mass index; BP blood pressure; EHT essential hypertension; IVS interventricular septum; LVID left
ventricular internal diameter; LVM left ventricular mass; LVMI left ventricular mass index; MAPmean arterial pressure;
NT  normotension; PW  posterior wall; WHT  white-coat hypertension.
Table 2. Daytime and Night-Time Ambulatory Characteristics of the Three Subject Groups:
NT, WHT and EHT
Variables NT WHT EHT
Comparisons
NT vs. WHT WHT vs. EHT
Daytime systolic BP (mm Hg) 121  1.3 123  2.3 144  2.1 p  0.05 p  0.001
Daytime diastolic BP (mm Hg) 76  1.5 77  0.6 87  1.8 p  0.05 p  0.001
Daytime MAP (mm Hg) 91  1.1 92  0.9 106  1.5 p  0.05 p  0.001
Daytime heart rate (beats/min) 81  0.6 81  2.1 79  2.0 p  0.05 p  0.05
Night-time systolic BP (mm Hg) 99  1.2 103  1.6 121  3.8 p  0.05 p  0.001
Night-time diastolic BP (mm Hg) 66  0.3 66  1.2 75  2.2 p  0.05 p  0.001
Night-time MAP (mm Hg) 77  0.6 78  1.1 90  2.5 p  0.05 p  0.001
Night-time heart rate (beats/min) 66  2.9 69  1.6 72  3.0 p  0.05 p  0.05
Data presented as mean  SEM. Statistical analyses between groups (Newman-Keuls; one-way analysis of variance) are shown
on the right.
Abbreviations as in Table 1.
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data between the three groups. The relation between sys-
tolic blood pressure and pulse interval was examined using
regression analysis. Values of p 0.05 were considered
statistically significant. Data are presented as mean  SEM.
RESULTS
The clinical data from the three groups NT, WHT and
EHT are shown in Table 1. The groups were well matched
for age and BMI. There were no significant differences in
echocardiographic measurements of PW, IVS and LVID
and in the derived LVM and LVMI. As expected, clinic
arterial blood pressure was significantly greater in EHT and
WHT than in NT. Also, the heart rate was significantly
higher in WHT as compared with both NT and EHT. The
ambulatory blood pressure data for the groups are shown in
Table 2. As anticipated, the values in EHT were signifi-
cantly greater than either WHT or NT. There was no
significant difference between the groups with respect to
either daytime or night-time heart rate.
As can be seen in Table 3 and Figures 1 and 2, the
frequency of MSNA both in terms of multiunit bursts and
single-unit activity was significantly greater in WHT than
in NT, but significantly smaller than that in EHT, when
expressed per 100 cardiac beats. Similar findings were found
when MSNA was expressed per minute, though this did not
reach statistical significance between WHT and EHT,
reflecting the greater heart rate in WHT. As compared with
NT, single-unit discharge was 46% greater in WHT and
approximately twice as much in EHT. Similar differences,
although of a lesser magnitude, were seen in MSNA
between the groups. A similar trend was found regarding
the difference in CVR between the groups, with CVR being
greatest in the EHT group. Both WHT and NT had
similar BRS levels, which were significantly greater than in
EHT (Table 3, Fig. 3).
Table 3. Findings in the Three Groups of Subjects: NT, WHT and EHT
Variables NT WHT EHT
Comparisons
NT vs. WHT WHT vs. EHT
s-MSNA (impulses/100b) 37  5.4 54  4.2 73  5.2 p  0.05 p  0.05
s-MSNA (impulses/min) 23  3.1 39  3.1 47  4.0 p  0.01 p  0.05
MSNA (bursts/100b) 34  4.4 47  3.8 58  2.6 p  0.05 p  0.05
MSNA (bursts/min) 21  2.6 35  2.7 39  2.1 p  0.001 p  0.05
CVR (U) 32  2.4 43  4.5 59  2.4 p  0.05 p  0.01
BRS (ms/mm Hg) 6.4  0.8 5.4  0.8 2.6  0.6 p  0.05 p  0.05
Data presented as mean  SEM. Statistical analyses between groups (Newman-Keuls; one-way analysis of variance) are shown
on the right.
BRS cardiac baroreceptor reflex sensitivity; CVR calf vascular resistance; MSNAmultiunit sympathetic nerve activity;
s-MSNA  single-unit muscle sympathetic nerve activity, expressed per 100 cardiac beats (100b) and per min; other
abbreviations as in Table 1.
Figure 1. The mean frequency of single-unit muscle sympathetic nerve
activity (s-MSNA) in the three groups of subjects, NT (normotension),
WHT (white-coat hypertension) and EHT (essential hypertension) ex-
pressed as mean (height of columns) and SEM (bars). Symbols represent
statistical analysis between groups; *p  0.05 and †p  0.05.
Figure 2. The mean frequency of muscle sympathetic nerve activity
(MSNA) bursts in the three groups of subjects, NT (normotension), WHT
(white coat hypertension) and EHT (essential hypertension) expressed as
mean (height of columns) and SEM (bars). Symbols represent statistical
analysis between groups; *p  0.05 and †p  0.05.
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DISCUSSION
Using the technique of microneurography, this investigation
has shown for the first time that, in the clinical setting,
WHT is associated with an increased MSNA relative to
that found in subjects with normal blood pressure (NT);
however, the level of sympathetic activity was not as great as
that found in patients with EHT. The observed sympathetic
hyperactivity in WHT could not be explained by differences
in age, BMI or arterial blood pressure.
Patient matching. To avoid confounding factors, we only
examined Caucasian subjects, as reported evidence suggests
that race can affect the responses of MSNA (34). All studies
were undertaken within the same environmental conditions
and after a light breakfast with an empty urinary bladder, as
visceral distension is known to increase sympathetic activity
(35,36). The three groups were matched for age (37) and
BMI (38,39). The finding that the patients with WHT had
a higher heart rate than the other two groups was not
unexpected, as this has previously been reported (2,3,40). In
view of the known effect of blood pressure level on the
magnitude of sympathetic activity in EHT (6,7,21,29), the
groups with WHT and EHT were also matched for clinic
blood pressure. In addition, there was no significant differ-
ence in either daytime or night-time ambulatory blood
pressure between the NT and WHT groups.
Main findings. This study showed that sympathetic neural
hyperactivity occurred in WHT and EHT, though to a
lesser extent in WHT. Our findings in EHT are in keeping
with previous publications confirming the presence of pe-
ripheral sympathetic hyperactivity in the clinical setting
(6–9). In addition, the present study shows for the first time
that peripheral sympathetic hyperactivity exists in WHT in
a similar clinical environment. In a previous report involving
a group of patients with mild hypertension combined with
the “white-coat effect,” it was found that MSNA bursts
decreased during a doctor’s visit by an average of 26% (22).
Even if such a decrease in MSNA has occurred in our study,
the finding of a greater MSNA in WHT than NT still
supports the conclusion that sympathetic hyperactivity exists
in WHT. In addition, the consideration of an increase in
sympathetic output in our WHT patients is consistent with
reports showing elevated plasma noradrenaline levels in
WHT (23). The greater heart rate in WHT relative to NT
and EHT in the clinical environment may be the result of
central effects culminating in an altered balance of sympa-
thetic and vagal effects on the sinoatrial node.
Implications. This study may be considered to help un-
ravel the mechanism of sympathetic hyperactivity in WHT.
The observed increase in sympathetic output occurred in
both the single-unit action potentials and the multiunit
bursts. The single-unit activity appears to provide a more
objective and quantitative estimation of sympathetic dis-
charge than that of multiunit bursts (21,26). In addition, as
the frequency of firing of the single unit is unaffected by
other recruited units, it is possible that they reflect the true
central tone of the peripheral nervous system (21). The
possibility of a central sympathetic activation is also consis-
tent with our findings that the increase in sympathetic
output could not be explained by known confounding
factors, such as visceral reflexes or the level of arterial
pressure. In addition, when WHT patients were assessed in
the clinical setting, blood pressure increased beyond that
observed during the daytime ambulatory monitoring. De-
spite this rise in blood pressure, we found an increase in
efferent sympathetic output rather than a decrease, which
would have been expected through intact baroreceptor reflex
control. This suggests that central effects and heterogeneity
of sympathetic control may have contributed to the observed
sympathetic hyperactivity and the rise of arterial blood
pressure. An example of such central heterogeneity has been
reported during isometric exercise testing (19), when the
pressor response is accompanied by an increase, rather than
a reflex decrease, in MSNA.
A further implication of this study is that a possible
pathogenic mechanism is suggested to account for the
increased prevalence of target organ damage reported to
occur in some patients with WHT, as compared with NT
(10–13,23). Indeed, there are two separate findings of the
present study that may be relevant. In the first instance,
although evidence exists to suggest that the baroreceptor
reflex control of MSNA is unaffected in EHT (29), an
impairment of cardiovagal baroreceptor reflex sensitivity has
also been reported in EHT (29,31), and this has been
suggested to imply an adverse prognosis in cardiovascular
disease (41). Our finding of a similar impairment of cardio-
vagal BRS in WHT and NT could be argued to suggest a
favorable prognosis in WHT. Conversely, sympathetic ac-
tivation is thought to be important in the development of
target organ damage in subjects with EHT (8,9). Therefore,
Figure 3. Cardiac baroreceptor sensitivity (BRS) in the three groups of
subjects, NT (normotension), WHT (white coat hypertension) and EHT
(essential hypertension) expressed as mean (height of columns) and SEM
(bars). Symbols represent statistical analysis between groups; *p  0.05
and †p  0.05.
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it seems reasonable to speculate from our findings that
sympathetic hyperactivity can occur in WHT, albeit on an
intermittent basis, and that this may constitute one mech-
anism leading to the development of target organ damage.
These arguments are further supported by the present
finding of a slightly greater left ventricular mass in WHT
and EHT as compared with NT. This occurred despite the
fact that we excluded patients who were found to have
obvious signs of left ventricular hypertrophy, as the latter
has been shown to be associated with sympathetic hyperac-
tivity (42). These considerations lend support to the view
that WHT may not be an entirely benign condition, and
could constitute an early manifestation of essential hyper-
tension (1,12,23).
Conclusions. The present investigation has shown that
WHT was associated with peripheral sympathetic hyperac-
tivity in the clinic setting, although this was not as excessive
as that seen in EHT. It is suggested that the sympathetic
hyperactivity was due to central, rather than reflex, mecha-
nisms, and this resulted in the blood pressure rise seen in
WHT. The findings also support the view that WHT is not
entirely innocent and may represent a prehypertensive state.
Acknowledgments
The authors thank Mr. J. Bannister, Mrs. J. Corrigan and
Miss J. Hebden for their technical assistance.
Reprint requests and correspondence: Dr. Paul A. Smith,
Cardio-Respiratory Unit, St. James’s University Hospital, Beckett
Street, Leeds, United Kingdom. E-mail: paulsmith.leeds@
ukgateway.net.
REFERENCES
1. Middeke M, Lemmer B. Office hypertension: abnormal blood pressure
regulation and increased sympathetic activity compared with normo-
tension. Blood Press Monit 1996;1:403–7.
2. Mansoor GA, White WB. Is white-coat hypertension innocent or
detrimental? Blood Press Monit 1999;4:241–7.
3. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Task
force V: white-coat hypertension. Blood Press Monit 1999;4:333–41.
4. Verdecchia P. White coat hypertension in adults and children. Blood
Press Monit 1999;4:175–9.
5. Folkow B. Physiological aspects of primary hypertension. Physiol Rev
1982;62:347–504.
6. Mark AL. Regulation of sympathetic nerve activity in mild human
hypertension. J Hypertens 1990;8 Suppl 7:S67–75.
7. Julius S, Nesbitt S. Sympathetic overactivity in hypertension: a moving
target. Am J Hypertens 1996;9:113s–20s.
8. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis
in hypertension. Eur Heart J 1998;19 Suppl F:F14–8.
9. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic
activation in the pathogenesis of hypertension and progression of
organ damage. Hypertension 1999;34:724–8.
10. Palatini P, Dorigatti F, Roman E, et al. White-coat hypertension: a
selection bias? Harvest study investigators: Hypertension and Ambu-
latory Recording Venetia study. J Hypertens 1998;16:977–84.
11. Palatini P, Mormino P, Santonastaso M, et al. Target-organ damage
in stage I hypertensive subjects with white coat and sustained hyper-
tension: results from the HARVEST study. Hypertension 1998;31:
57–63.
12. Owens PE, Lyons SP, Rodriguez SA, O’Brien ET. Is elevation of
clinic blood pressure in patients with white coat hypertension who
have normal ambulatory blood pressure associated with target organ
changes? J Hum Hypertens 1998;12:743–8.
13. Glen SK, Elliott HL, Curzio JL, Lees KR, Reid JL. White coat
hypertension as a cause of cardiovascular dysfunction. Lancet 1996;
348:654–7.
14. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C.
White-coat hypertension: not guilty when correctly defined. Blood
Press Monit 1998;3:147–52.
15. Pierdomenico SD, Lapenna D, Guglielmi MD, et al. Target organ
status and serum lipids in patients with white coat hypertension.
Hypertension 1995;26:801–7.
16. Gosse P, Promax H, Durandet P, Clementy J. “White coat” hyper-
tension: no harm for the heart. Hypertension 1993;22:766–70.
17. Cavallini MC, Roman MJ, Pickering TG, Schwartz JE, Pini R,
Devereux RB. Is white coat hypertension associated with arterial
disease or left ventricular hypertrophy? Hypertension 1995;26:413–9.
18. Vallbo AB, Hagbarth KE, Torebjo¨rk HE, Wallin BG. Somatosen-
sory, proprioceptive and sympathetic activity in human peripheral
nerves. Physiol Rev 1979;59:919–57.
19. Wallin BG. Assessment of sympathetic mechanisms for recordings of
postganglionic efferent nerve traffic. In: Hainsworth R, Mark AL,
editors. Cardiovascular Reflex Control in Health and Disease. Phila-
delphia, PA: WB Saunders, 1993:65–93.
20. Grassi G, Esler M. How to assess sympathetic activity in humans.
J Hypertens 1999;17:719–34.
21. Greenwood JP, Stoker JB, Mary DASG. Single-unit sympathetic
discharge: quantitative assessment in human hypertensive disease.
Circulation 1999;100:1305–10.
22. Grassi G, Turri C, Vailati S, Dell’ Oro R, Mancia G. Muscle and skin
sympathetic nerve traffic during the “white-coat” effect. Circulation
1999;100:222–5.
23. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of
mild hypertension by ambulatory blood pressure monitoring. Circula-
tion 1994;90:2291–8.
24. Pierdomenico SD, Bucci A, Costantini F, Lapenna D, Cuccurullo F,
Mezzetti A. Twenty-four-hour autonomic nervous function in sus-
tained and “white coat” hypertension. Am Heart J 2000;140:672–7.
25. Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. The sixth report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. Arch Intern Med 1997;157:2413–46.
26. Macefield VG, Wallin BG, Vallbo AB. The discharge behaviour of
single vasoconstrictor motoneurones in human muscle nerves. J Physiol
(Lond) 1994;481:799–809.
27. Sundlo¨f G, Wallin BG. The variability of muscle nerve sympathetic
activity in resting recumbent man. J Physiol (Lond) 1977;272:383–97.
28. Kautzner J, Hartikainen JE, Camm AJ, Malik M. Arterial baroreflex
sensitivity assessed from phase IV of the Valsalva maneuver. Am J
Cardiol 1996;78:575–9.
29. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G.
Baroreflex control of sympathetic nerve activity in essential and
secondary hypertension. Hypertension 1998;31:68–72.
30. Trimarco B, Volpe M, Ricciardelli B, et al. Valsalva maneuver in the
assessment of baroreflex responsiveness in borderline hypertensives.
Cardiology 1983;70:6–14.
31. Mancia G, Grassi G. Baroreceptor control of the circulation in man:
an update. Clin Exper Hypertens 1995;17:387–97.
32. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations
regarding quantification in M-mode echocardiography: results of a
survey of echocardiographic measurements. Circulation 1978;58:
1072–83.
33. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic
assessment of left ventricular hypertrophy: comparison to necropsy
findings. Am J Cardiol 1986;57:450–8.
34. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S.
Normotensive blacks have heightened sympathetic response to cold
pressor test. Hypertension 1993;22:801–5.
35. Fagius H, Karhuvaara S. Sympathetic activity and blood pressure
increases with bladder distension in humans. Hypertension 1989;14:
511–7.
36. Cox HS, Kaye DM, Thompson JM, et al. Regional sympathetic
nervous activation after a large meal in humans. Clin Sci (Colch)
1995;89:145–54.
131JACC Vol. 40, No. 1, 2002 Smith et al.
July 3, 2002:126–32 Sympathetic Hyperactivity in White-Coat Hypertension
37. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence
muscle sympathetic nerve activity at rest in healthy humans. Hyper-
tension 1993;21:498–503.
38. Andersson B, Elam M, Wallin BG, Bjorntorp P, Andersson OK.
Effect of energy-restricted diet on sympathetic muscle nerve activity in
obese women. Hypertension 1991;18:783–9.
39. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P.
Body fat and sympathetic nerve activity in healthy subjects. Circulation
1994;89:2634–40.
40. Julius S, Mejia A, Jones K, et al. “White coat” versus “sustained”
borderline hypertension in Tecumseh, Michigan. Hypertension 1990;
16:617–23.
41. Ylitalo A, Airaksinen J, Sellin L, Huikuri HV. Effects of combination
antihypertensive therapy on baroreflex sensitivity and heart rate vari-
ability in systemic hypertension. Am J Cardiol 1999;83:885–9.
42. Greenwood JP, Scott EM, Stoker JB, Mary DASG. Hypertensive left
ventricular hypertrophy: relation to peripheral sympathetic drive. J Am
Coll Cardiol 2001;38:1711–7.
132 Smith et al. JACC Vol. 40, No. 1, 2002
Sympathetic Hyperactivity in White-Coat Hypertension July 3, 2002:126–32
